Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in Cambridge, MA. Its footprint includes major operating, manufacturing, commercial, R&D, laboratory, technology, clinical, or distribution hubs across the United States and international markets.
- HQ
- Cambridge, MA
- HQ address
- 675 West Kendall Street, Cambridge, MA 02142
- Offices
- Cambridge, MA; Norton, MA; Amsterdam, Netherlands; Maidenhead, UK
- Founded
- 2002
- Employees
- 2,500+
- Largest hub
- Cambridge, MA
Alnylam Pharmaceuticals office locations
Alnylam Pharmaceuticals's public footprint includes headquarters and major operating hubs used for executive, commercial, clinical, manufacturing, distribution, laboratory, or technology work.
- Cambridge, MA· Headquarters
- Norton, MA· Office
- Amsterdam, Netherlands· Office
- Maidenhead, UK· Office
- Zug, Switzerland· Office
- Tokyo, Japan· Office
- Munich, Germany· Office
Sources:Alnylam Pharmaceuticals websiteAlnylam Pharmaceuticals annual reports
Where is Alnylam Pharmaceuticals's headquarters?
Alnylam Pharmaceuticals's headquarters is listed as Cambridge, MA, with a public headquarters address of 675 West Kendall Street, Cambridge, MA 02142. Executive, investor, legal, finance, and enterprise procurement routes are usually tied to this corporate center even when the operational buyer sits elsewhere.
What other offices does Alnylam Pharmaceuticals have?
The footprint includes Cambridge, MA, Norton, MA, Amsterdam, Netherlands, Maidenhead, UK, Zug, Switzerland, Tokyo, Japan, Munich, Germany. For healthcare companies, these locations often split by business-unit leadership, R&D, manufacturing, distribution, commercial teams, technology, clinical operations, laboratory operations, and international market coverage.
What Alnylam Pharmaceuticals's office footprint means for territory planning
Territory planning should not treat the headquarters as the only buyer location. Field events and account mapping should follow business-unit hubs, hospital or clinic markets, laboratory and manufacturing nodes, technology centers, and executive travel patterns. Time-zone coverage matters because approvals can involve stakeholders across multiple regions.
As of June 2026.Sources:Alnylam Pharmaceuticals websiteAlnylam Pharmaceuticals annual reportsAlnylam Pharmaceuticals contact
Alnylam Pharmaceuticals — frequently asked questions
